. Coronavirus (SARS-CoV2) appeared first in China late 2019 and caused an acute respiratory disease referred to as Coronavirus disease 2019 (COVID-19). SARS-CoV2 is considered by the World Health Organization (WHO) as pandemic and affected nations worldwide, leading to close borders and major economical struggle. The ongoing viral threat due to the lack of effective therapies and vaccination might prolonged this economical challenge and many businesses will face huge financial constraints leading to laying off labors, an increase in the unemployment rate, and major companies' bankruptcies. However, returning to normal business operations should be done with a safety focus and not be at the cost of global health and wellbeing. Immunity against COVID-19 is going to be a major determinant for a future safe work environment and will reduce the viral infection risk. Therefore, PI is suggesting that if an employee has antibodies against SARS-CoV-2 confirmed by serological testing, he or she could go back to work safely with taking the necessary precautions.
Coronavirus (SARS-CoV2) appeared first in China late 2019 and caused an acute respiratory
disease referred as Coronavirus disease 2019 (covid-19). SARS-CoV2 is considered by the World
Health Organization (WHO) as pandemic and affected nations worldwide, leading to close
borders and major economical struggle. The ongoing viral threat due to the lack of effective
therapies and vaccination might prolonged this economical challenge and many businesses will
face huge financial constrains leading to laying off labors, increase in the unemployment
rate and major companies' bankruptcies. However, returning to normal business operation
should be done with a safety focus and not be at the cost of the global health and wellbeing.
Immunity against COVID-19 is going to be a major determinant for future safe work environment
and will reduce the viral infection risk. Therefore, PI is suggesting that if an employee has
antibodies against SARS-CoV-2 confirmed by serological testing, he or she could go back to
work safely with taking the necessary precautions.
Materials and Methods: Oncology medical staffs directly involved with patients will be
serologically tested using the SARS-CoV-2 IgG assay kit (Abbott Diagnostics, US). If
Participants were IgG positive, partcipants will be assumed as immune and therefore, could
join the work forces. If partcipants tested negative, partcipants will undergo molecular
testing using the RealStar® SARS-CoV-2 RT-PCR Kit RUO (Altona Diagnostics, Germany) to
confirm freedom from COVID-19 and then partcipants could join as safe work environment.
However, if Positive PCR, partcipants will be quarantined for 14 days or until 2 negative PCR
obtained as per the standard Saudi Ministry of Health (MOH) guidelines.
Conclusion: by confirming that healthcare providers have antibodies against SARS-CoV-2 virus
and/or their respiratory samples prove the absence of the virus, they can be considered safe
and can report to work. By doing so, PI could facilitate going back to normal life and
ultimately help improving healthcare functionality as well as overall businesses operation.
Diagnostic Test: molecular testing for virus RNA using RT-PCR
Serological testing will be performed using SARS-CoV-2 IgG assay kit (Abbott Diagnostics, US) to check for the immunity. The IgG serology test (200 individuals per run) will be done using ARCHITECT i2000SR system which provides the results within 60 minutes
Inclusion Criteria:
- all Health care provider at KFSH D
Exclusion Criteria:
- NA
king Fahad specialist hospital
Dammam, Eastern Province, Saudi Arabia
Investigator: Hani Al Hashmi, MD
Contact: 00966564773377
hashmih@yahoo.com
Investigator: